Improving patient access to expensive drugs, paving the way for entry of their cheaper generic equivalents, post patent expiry, and avoiding evergreening, is assuming priority a priority focus area in many countries. The United States is no exception, in this … Continue reading
Tag Archives: PhRMA
Reticence Around Unveiling Clinical Trials
While scanning through various publications, we now get to know, almost at regular intervals, about new clinical trials capturing the newer ways of treating different ailments. Such information instils an invigorating hope in the minds of doctors and the patients … Continue reading
Arbitrary Pricing of Essential Drugs Invites State Intervention
Arbitrary drug pricing has now become a subject of a raging debate, all over the globe. It involves both patented and generic drugs, as we have recently witnessed in the largest pharma market in the world – the United States. … Continue reading
‘The Memory Thief’ Still Eludes Grasp Of Pharma R&D
Over several decades, in fact, since its very inception, pharma R&D has been playing a crucial role in alleviating diseases of various types – from severe acute infections, to a large variety of non-infectious chronic illnesses, including many dreaded diseases, … Continue reading
A Patient-Centric State Initiative To Revolutionize Disease Treatment
In his State of the Union address, just before the recent visit to India in January 2015, President Barack Obama articulated the need to develop “Precision Medicine” in his country – a bold, giant and perhaps unprecedented State initiative to … Continue reading
New “National IPR Policy” of India – A Pharma Perspective
Whether under pressure or not, is hardly of any relevance now. What is relevant today is the fact that the new Indian Government, almost in a record time of just around two months, has been able to release a high … Continue reading
Unilateral American Action on Agreed Bilateral Issues: Would India Remain Unfazed?
I discussed in one of my earlier blog posts titled “Has Prime Minister Modi Conceded Ground To America On Patents Over Patients?” of October 6, 2014 that on April 30, 2014, the United States in its report on annual review … Continue reading
Leading Through The Challenge Of Change: Is Pharma Leadership Too Archaic?
A recent major global survey titled “Testing The Health Of The Pharmaceutical Industry” has revealed that a sizable majority of executives polled, though believe the sector is in good shape, are concerned of its reputation. Interestingly, 73 percent of respondents believe … Continue reading